Market closed
Caribou Biosciences/$CRBU
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Caribou Biosciences
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
Ticker
$CRBU
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
158
Website
CRBU Metrics
BasicAdvanced
$100M
-
-$1.65
2.34
-
Price and volume
Market cap
$100M
Beta
2.34
52-week high
$7.24
52-week low
$1.01
Average daily volume
1.2M
Financial strength
Current ratio
7.157
Quick ratio
6.942
Long term debt to equity
9.907
Total debt to equity
10.471
Management effectiveness
Return on assets (TTM)
-27.18%
Return on equity (TTM)
-47.99%
Valuation
Price to revenue (TTM)
9.67
Price to book
0.39
Price to tangible book (TTM)
0.39
Price to free cash flow (TTM)
-0.668
Growth
Revenue change (TTM)
-71.01%
Earnings per share change (TTM)
19.38%
3-year revenue growth (CAGR)
1.36%
3-year earnings per share growth (CAGR)
-7.91%
What the Analysts think about CRBU
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Caribou Biosciences stock.
CRBU Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CRBU Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CRBU News
AllArticlesVideos
Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Investors to Inquire about Securities Investigation
Accesswire·2 days ago
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewsWire·3 days ago
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
GlobeNewsWire·6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Caribou Biosciences stock?
Caribou Biosciences (CRBU) has a market cap of $100M as of March 13, 2025.
What is the P/E ratio for Caribou Biosciences stock?
The price to earnings (P/E) ratio for Caribou Biosciences (CRBU) stock is 0 as of March 13, 2025.
Does Caribou Biosciences stock pay dividends?
No, Caribou Biosciences (CRBU) stock does not pay dividends to its shareholders as of March 13, 2025.
When is the next Caribou Biosciences dividend payment date?
Caribou Biosciences (CRBU) stock does not pay dividends to its shareholders.
What is the beta indicator for Caribou Biosciences?
Caribou Biosciences (CRBU) has a beta rating of 2.34. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.